Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COCP Cocrystal Pharma	$1.49 -3.9%	$1.51	$1.12 ▼ $3.26	N/A	2.15	26,616 shs	18,037 shs
ICOTF iCo Therapeutics	$0.39 -4.4%	$0.37	$0.80 ▼ $1.82	$3.56M	2.03	4,760 shs	102,500 shs
LPTX Leap Therapeutics	$0.38 -2.7%	$0.39	$0.22 ▼ $4.79	$15.75M	-0.22	847,426 shs	274,427 shs
UBX UNITY Biotechnology	$0.81 +1.9%	$0.85	$0.66 ▼ $3.10	$13.85M	1.06	164,385 shs	80,080 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COCP Cocrystal Pharma	0.00%	-3.25%	+2.05%	-5.70%	-43.98%
ICOTF iCo Therapeutics	0.00%	-4.15%	-22.94%	-27.22%	-16.38%
LPTX Leap Therapeutics	0.00%	-7.29%	+4.22%	-2.56%	-80.21%
UBX UNITY Biotechnology	0.00%	+0.88%	+3.34%	-38.08%	-42.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COCP Cocrystal Pharma	1.8345 of 5 stars	3.5	3.0	0.0	0.0	0.9	1.7	0.0
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	1.9481 of 5 stars	3.1	4.0	0.0	0.0	0.6	0.0	1.3
UBX UNITY Biotechnology	3.3377 of 5 stars	3.3	2.0	0.0	4.7	0.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COCP Cocrystal Pharma	3.00	Buy	$6.00	302.68% Upside
ICOTF iCo Therapeutics	0.00	N/A	N/A	N/A
LPTX Leap Therapeutics	2.25	Hold	$4.92	1,193.86% Upside
UBX UNITY Biotechnology	2.50	Moderate Buy	$3.75	365.84% Upside

Current Analyst Ratings Breakdown

Latest ICOTF, UBX, COCP, and LPTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	COCP Cocrystal Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
5/27/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$4.00 ➝ $2.00
5/16/2025	UBX UNITY Biotechnology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$6.00 ➝ $1.00
4/23/2025	UBX UNITY Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/23/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/27/2025	LPTX Leap Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/25/2025	UBX UNITY Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
3/24/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.94 per share	N/A
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$0.91 per share	N/A
UBX UNITY Biotechnology	$240K	57.73	N/A	N/A	$0.39 per share	2.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COCP Cocrystal Pharma	-$17.50M	-$1.57	N/A	N/A	N/A	N/A	-135.12%	-102.38%	8/13/2025 (Estimated)
ICOTF iCo Therapeutics	-$1.11M	-$0.40	N/A	∞	N/A	N/A	N/A	-288.85%	N/A
LPTX Leap Therapeutics	-$67.56M	-$1.70	N/A	N/A	N/A	N/A	-162.15%	-120.05%	8/11/2025 (Estimated)
UBX UNITY Biotechnology	-$25.99M	-$1.62	N/A	N/A	N/A	N/A	-246.82%	-58.81%	7/22/2025 (Estimated)

Latest ICOTF, UBX, COCP, and LPTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	COCP Cocrystal Pharma	-$0.52	-$0.23	+$0.29	-$0.23	N/A	N/A
5/13/2025	Q1 2025	LPTX Leap Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	N/A	N/A
4/22/2025	Q1 2025	UBX UNITY Biotechnology	-$0.43	-$0.43	N/A	-$0.43	N/A	N/A
3/27/2025	Q4 2024	COCP Cocrystal Pharma	-$0.55	-$0.32	+$0.23	-$0.32	N/A	N/A
3/26/2025	Q4 2024	LPTX Leap Therapeutics	-$0.39	-$0.37	+$0.02	-$0.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A
UBX UNITY Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COCP Cocrystal Pharma	N/A	4.57	4.57
ICOTF iCo Therapeutics	N/A	0.72	0.72
LPTX Leap Therapeutics	N/A	2.41	2.41
UBX UNITY Biotechnology	N/A	1.95	1.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COCP Cocrystal Pharma	6.72%
ICOTF iCo Therapeutics	N/A
LPTX Leap Therapeutics	30.46%
UBX UNITY Biotechnology	29.49%

Insider Ownership

Company	Insider Ownership
COCP Cocrystal Pharma	28.14%
ICOTF iCo Therapeutics	N/A
LPTX Leap Therapeutics	7.50%
UBX UNITY Biotechnology	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COCP Cocrystal Pharma	10	N/A	N/A	Not Optionable
ICOTF iCo Therapeutics	N/A	9.05 million	N/A	Not Optionable
LPTX Leap Therapeutics	40	41.44 million	38.33 million	Optionable
UBX UNITY Biotechnology	60	17.21 million	16.21 million	Optionable

ICOTF, UBX, COCP, and LPTX Headlines

Recent News About These Companies

HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)

May 28, 2025 | msn.com

Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities

May 18, 2025 | theglobeandmail.com

Bay Area biotech company Unity lays off every single worker, including CEO

May 7, 2025 | msn.com

Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce

May 5, 2025 | msn.com

South San Francisco biotech company lays off entire workforce, including CEO

May 5, 2025 | msn.com

Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles

May 5, 2025 | fiercebiotech.com

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

May 1, 2025 | globenewswire.com

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325

April 25, 2025 | ophthalmologytimes.com

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

April 22, 2025 | globenewswire.com

Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology price target lowered to $4 from $6 at Chardan

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology announces results from ASPIRE Phase 2b study in DME

March 25, 2025 | markets.businessinsider.com

Unity reports topline outcomes from trial of diabetic macular oedema therapy

March 25, 2025 | msn.com

UNITY Biotechnology tanks on mixed results for eye disease drug

March 25, 2025 | thepharmaletter.com

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

March 25, 2025 | zacks.com

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

March 24, 2025 | finance.yahoo.com

Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema

March 24, 2025 | ophthalmologytimes.com

UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial

March 24, 2025 | msn.com

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls

March 24, 2025 | benzinga.com

UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

March 24, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICOTF, UBX, COCP, and LPTX Company Descriptions

Cocrystal Pharma NASDAQ:COCP

$1.49 -0.06 (-3.87%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.52 +0.03 (+2.01%)

As of 06/20/2025 04:21 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

iCo Therapeutics OTCMKTS:ICOTF

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

Leap Therapeutics NASDAQ:LPTX

$0.38 -0.01 (-2.66%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.38 +0.00 (+0.79%)

As of 06/20/2025 07:50 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

UNITY Biotechnology NASDAQ:UBX

$0.80 +0.01 (+1.87%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.81 +0.01 (+0.62%)

As of 06/20/2025 07:45 PM Eastern

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time